FDA widens clearance for Siesta's tongue suspension device

01/11/2013 | BeckersASC.com

The FDA has given Siesta Medical expanded clearance for the company's Encore tongue suspension device. The company, which is headquartered in Los Gatos, Calif., can now market the device for multiple suspension loop applications and as a fully adjustable system after implantation in patients with obstructive sleep apnea. "Siesta believes the Encore system is a ... cost effective surgical option for treating OSA patients unable to comply with CPAP use,” said company President and CEO Peter Martin.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX